245 results about "Post immunization" patented technology

The invention relates to the technical field of porcine pseudorabies viruses and especially relates to a gE- and gI-deleted porcine pseudorabies virus variant strain PRV-ZJ011G and a use thereof. The gE- and gI-deleted porcine pseudorabies virus variant strain PRV-ZJ011G has the accession number of CGMCC No.7957. The invention discloses the use of the gE- and gI-deleted porcine pseudorabies virus variant strain PRV-ZJ011G in vaccine preparation. After the New Zealand big white rabbit is inoculated with the 106.0TCID50 recombinant viruses, clinical symptoms such as pruritus are not caused. An oil-in-water inactivated vaccine prepared from the gE- and gI-deleted porcine pseudorabies virus variant strain PRV-ZJ011G is injected into a piglet and after four weeks, the BELISA antibody is produced but the gE antibody does not exist, and the immunization protection efficiency is 100%. After immunization on sows, the piglets produced by the sows get immunization protection and the efficiency of PRV variant virus and traditional virus immunization protection is 100%. It is proved that the ZJ011G recombinant virus has good immunogenicity and can be used for vaccine preparation.

The invention, which belongs to the technical field of vaccines, particularly relates to an African swine fever B and T cell tandem epitope fusion vaccine. The main component of the African swine fever B and T cell tandem epitope fusion vaccine is African swine fever tandem epitope fusion protein. The African swine fever tandem epitope fusion protein comprises a B cell neutralizing epitope peptidefragment and a T cell epitope; and the B cell neutralizing epitope peptide comprises the following fragments: at least one neutralizing epitope peptide of each of p72, p54, p30 proteins. When the African swine fever tandem epitope fusion protein is used as a vaccine, the immune effect is good; and the antibody level significantly higher than that of a control group can be detected after one immunization. Since the non-neutralizing epitope is reduced as much as possible in the fusion protein, the risk of accelerating virus infection (ADE effect and antibody dependence enhancement effect) by anon-neutralizing antibody after immunization can be avoided.

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic dodecapeptide. The method comprises the following steps: synthesizing a polypeptide with a "CGYGAGAGAGYGA" sequence, coupling the polypeptide with keyhole limpet hemocyanin (KLH) so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, carrying out an emulsion treatment so as to obtain primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then carrying out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antiserum titer of rabbit arrives at 1 / 10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate. The antibody prepared by the invention has a strong specificity, and can be used for detection and analysis of silk fibroin in textile, and the like.

The present invention provides a process for characterizing a glatiramer acetate related drug substance or drug product comprising the steps of:a) obtaining a batch of the glatiramer acetate related drug substance or drug product;b) immunizing a mammal with a predetermined amount of a glatiramer acetate related drug substance or drug product;c) preparing a culture of cells from the mammal of step b) at a predetermined time after immunization;d) incubating cells from the culture of step c) with a predetermined amount of the glatiramer acetate drug related substance or drug product of step a); ande) determining the level of expression of at least one gene disclosed herein or determining the level of biological activity of the cells of step c) as disclosed herein,thereby characterizing the glatiramer acetate related drug substance or drug product of step a).

The invention relates to the field of haemophilus parasuis vaccines in veterinary biological products, in particular to a haemophilus parasuis LC strain. The collection number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.5257. The invention also relates to application of the haemophilus parasuis LC strain to preparation of haemophilus parasuis inactivated vaccines. The haemophilus parasuis LC strain has stronger pathogenicity to pigs and has better immunogenicity; an inactivated alumina gel vaccine prepared by the strain is safe and reliable; not only a homologous attacking protection is provided, but also a better cross protection to blood serums type 4, type 5, type 10, type 12, type 14 and type 15 HPS (Hantavirus Pulmonary Syndrome) heterologous attacking can be provided; after the pigs are immunized, a stronger immunity can be generated and the morbidity and the mortality of the inoculated pigs are obviously reduced; the immune effect achieves or is better than the traditional commercialized vaccines in the market; the vaccine has the advantages to compete with like products at home and abroad and is capable of effectively preventing the epidemic and the transmission of a haemophilus parasuis disease and reducing the economic losses caused by the disease, so that the application range is wide.

The invention discloses a preparation method of a porcine epidemic diarrhea recombinant adenovirus vaccine. The preparation method provided by the invention comprises the following steps of inserting a DNA sequence of a zone S1 of a porcine epidemic diarrhea virus (PEDV) into an adenovirus shuttle plasmid pShuttle-CMV to obtain pShuttle-CMV-S1, carrying out linearization of the pShuttle-CMV-S1, transforming the linear pShuttle-CMV-S1 into a BJ5183 competent cell containing pAdEasy-1, carrying out homologous recombination, carrying out enzyme digestion, carrying out AD-293 cell transfection, carrying out packaging to obtain a recombinant adenovirus rAd-S1, and carrying out purification, amplification and sub-packaging. After oral immunization, the porcine epidemic diarrhea recombinant adenovirus vaccine can induce generation of mucosal immunity thereby preventing porcine epidemic diarrhea (PED) well.

The invention belongs to the field of detection of harmful biological molecules in food, and relates to a preparation method and application of an Aspergillus flavus specific single-chain antibody. The cell wall proteins of the Aspergillus flavus hypha are used for immunizing chickens and mice respectively; messenger RNA of chicken splenic lymphocytes after immunization are extracted; a chicken source single-chain antibody library is constructed; a phage display technology is employed to screen the library to obtain an Aspergillus specific single-chain antibody gene with high affinity to Aspergillus flavus. The antibody gene is subcloned into an expression vector of an alkaline phosphatase protein, and expressed and purified in Escherichia coli, so as to obtain a fusion protein and a hybridoma cell 2A8 secreting Aspergillus flavus specific monoclonal antibody. The monoclonal antibody as a capture antibody and AfSA4-AP fusion protein as a detection antibody are employed to establish a SandWich ELISA immunological detection system for detecting Aspergillus flavus contamination in crops and stored plant-derived products.

The invention discloses a fusion protein comprising an Fc domain of IgG and an extracellular domain of an EB virus envelope glycoprotein. The fusion protein is represented by the following formula: P-E-F, wherein P represents a secretion signal peptide, E represents an amino acid sequence of the extracellular domain of the EB virus envelope glycoprotein gp350, and F represents the amino acid sequence of the Fc domain of the IgG. It is found for the first time that after the fusion of the Fc domain of the immunoglobulin IgG with the envelope glycoprotein gp350 from the surface of the EB virus,the immunogenicity in vivo is significantly improved. After immunization with the fusion protein, the total serum titer an immunized animal, the serum specific neutralizing antibody titer and the serum in vitro viral infection blocking efficiency are significantly higher than that of a non-fused control protein. The fusion protein using the Fc domain of the immunoglobulin IgG and the EB virus membrane glycoprotein is adopted as an evidence for the efficacy of an EB virus vaccine and has important practical and theoretical significance and application prospects for prevention and treatment of EB virus-related diseases.

The invention discloses an application of an inhibin recombinant fusion protein to preparing medicines for promoting oestrus and hybridization of sows. When inhibin is used for the sows: 0.5-1mg of the inhibin recombinant protein is used for initial immunization; and after 15-21 days, 0.25-0.5mg of the inhibin recombinant protein is used for second immunization. The immune inhibin can increase the estrus rate and the litter sizes of the sows. The invention has obvious effects on overcoming anestrus of the sows, caused by heat stress in summer, promoting the breeding activities of breeding sows, and particularly on promoting oestrus of breeding sows and back-up sows and increasing litter sizes. Thus, the non-productive time of the breeding sows is shortened, the breeding performance of thebreeding sows is improved, and the economic benefit of sow raising is increased.

The present invention relates to a method for screening protective antigens of grouper iridescent virus (SGIV), specifically the identification of protective antigen genes from grouper iridescent virus with vaccine development prospects, including bioinformatics analysis and DNA vaccine identification. Protective antigens were screened out by challenge after preparation and immunization. The present invention provides three protective antigen genes screened out from SGIV162 virus-encoded genes, and provides a method for analyzing and screening potential vaccine candidate antigens in virus-encoded genes, which is beneficial to the further development of new grouper iridescent The virus vaccine can effectively prevent and control grouper iridescent virus disease, and improve the survival rate and breeding efficiency of grouper.

The invention discloses methods for preparing a monoclonal antibody and a hybridoma cell strain thereof by multiple antigens in an immune high-flux manner. The method for preparing a hybridoma cell strain for secreting a specific monoclonal antibody by multiple antigens in the immune high-flux manner comprises the following steps of: 1) mixing n antigen proteins serving as immune antigens for immunizing a mice, thereby obtaining an immunized mice; 2) combining in-vitro spleen cells and SP2 / 0 myeloma cell of the immunized mice to obtain combined cells; 3) performing primary enzyme-linked immuno sorbent assay (ELISA) selection on the combined cells, and selecting hybridoma cells generating fos-like immunoreactivity; and 4) performing secondary ELISA selection on the hybridoma cells generating the fos-like immunoreactivity, and selecting the hybridoma cells aiming at single-antigen fos-like immunoreactivity. A high-flux technical method for obtaining multiple protein monoclonal antibodies by once cell combination is constructed; the time and the labor cost are saved for the preparation of the monoclonal antibodies; and contributions is made to improvement of the production efficiency of the monoclonal antibodies.

The invention relates to a production method of virus-inactivated plasma for treating COVID-19. The method comprises the following steps: (1) collecting convalescent plasma of COVID-19 survivors or plasma immune to a Severe Acute Respiratory Syndrome Coronavirus 2 vaccine (SARS-CoV-2 vaccine), and conducting pretreatment; (2) adding methylene blue, and conducting photo-inactivation on the plasma;and (3) conducting labeling and packaging after the plasma passes tests.

The invention discloses an infectious bursal disease antigen-antibody complex as well as a preparation and a preparation method thereof. The preparation method of the antigen-antibody complex comprises the following steps of: (1) preparing a VP2 protein as an antigen; (2) preparing an egg yolk antibody from an infectious bursal disease virus inactivated vaccine as an antibody; and (3) mixing the antigen and the antibody according to the prescription proportion, and performing sterilization treatment. The antigen-antibody complex preparation mainly refers to a common liquid preparation, an oil emulsion and a solid preparation prepared from the infectious bursal disease antigen-antibody complex. The antigen-antibody complex disclosed by the invention has the characteristics of stable performance, good safety, fast immunization effect after animal immunization, strong immunity and high protection rate; and the prepared complex preparation is simple and quick to prepare and safe and convenient to use.